Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIL204-SL
- Development stage
- Phase 3
- Lead developer
- Silexion Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
SIL204-SL is an siRNA-based therapeutic candidate developed by Silexion Therapeutics for the treatment of non-resectable locally advanced pancreatic cancer (LAPC) harboring KRAS mutations. It utilizes RNA interference (RNAi) to silence the expression of mutated KRAS, a primary oncogenic driver in pancreatic adenocarcinoma. The therapy is designed for both intratumoral delivery—often via a biodegradable polymeric scaffold (LODER) that provides sustained release—and systemic administration. SIL204-SL is currently being evaluated in an integrated Phase 2/3 trial (PROTACT) in combination with standard chemotherapy regimens, aiming to improve outcomes in patients with KRAS-mutated tumors by inhibiting tumor growth and enhancing sensitivity to chemotherapy.
02
Targets
Kirsten rat sarcoma viral oncogene homolog mRNAKRAS (Kirsten rat sarcoma viral oncogene homolog)
Beyond the preview
Go deeper on SIL204-SL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIL204-SL.